The seasonal influenza vaccines therapeutics market is projected to grow from USD 10.2 billion in 2025 to USD 24.1 billion by 2035, at a CAGR of 9.0%. Quadrivalent will dominate with a 64.5% market share, while adult will lead the age group segment with a 71.0% share.